Lymphoma, B-Cell: all 1,415 studies
Page 12 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02733380Phase 2
- DS-3201b in Participants With LymphomasActive, not recruitingNCT02732275Phase 1
- Marginal Zone Lymphoma Cohort in KoreaStatus unknownNCT02732236
- Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell LymphomaNo longer availableNCT02715843
- Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02708732
- A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaTerminatedNCT02702141Phase 1
- A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasTerminatedNCT02700022Phase 1
- The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell LymphomaCompletedNCT02679196Phase 1
- Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
- Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2
- Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell LymphomaCompletedNCT02660710Phase 2
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnNCT02653989Phase 2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesCompletedNCT02651662Phase 1
- CD22 Redirected Autologous T Cells for ALLActive, not recruitingNCT02650414Phase 1
- DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin LymphomasActive, not recruitingNCT02633111
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
- Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT02625480Phase 1/2
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell LymphomaWithdrawnNCT02595242Phase 1
- A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell LymphomaCompletedNCT02584920Phase 1/2
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 1
- Geriatric Assessments in Elderly Diffuse Large B-cell LymphomaCompletedNCT02555267
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1
- CD19-targeting CAR T Cells for B Cell LymphomaWithdrawnNCT02547948Phase 1/2
- A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
- A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaWithdrawnNCT02532192Phase 1
- Multicenter Prospective Registry Study of Diffuse Large B Cell LymphomaStatus unknownNCT02474550
- KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell LymphomaCompletedNCT02471911Phase 1
- A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaStatus unknownNCT02456207Phase 2
- A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT02453087Phase 1
- Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT02412267Phase 2
- Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02405078Early Phase 1
- A Study Evaluating CPI-1205 in Patients With B-Cell LymphomasCompletedNCT02395601Phase 1
- First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCLStatus unknownNCT02388581Phase 2
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)Status unknownNCT02354846
- A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCompletedNCT02343536Phase 1
- Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaCompletedNCT02340936Phase 1/2
- A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCLTerminatedNCT02323230Phase 2
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell LymphomasStatus unknownNCT02247609Phase 1/2
- An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical PracticeCompletedNCT02240316
- Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi SarcomaWithdrawnNCT02229981Phase 1/2
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.CompletedNCT02206308Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T LymphocytesStatus unknownNCT02134262Phase 1/2
- Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+CompletedNCT02128061Phase 3
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHLTerminatedNCT02106091Phase 1
- CART-19 Immunotherapy in Mantle Cell LymphomaStatus unknownNCT02081937Phase 1/2
- Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT02072967
- Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)Status unknownNCT02060656Phase 2
- Epstein-Barr Virus Status in Diffuse Large B Cell LymphomaCompletedNCT02060435
- Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell LymphomasTerminatedNCT02055924Phase 1
- R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCLWithdrawnNCT02054559Phase 3
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT02049541Phase 1
- A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced NeutropeniaCompletedNCT02044276Phase 3
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedNCT02031419Phase 1
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological MalignanciesCompletedNCT02017613Phase 1
- Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIbCompletedNCT02012088Phase 2
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.CompletedNCT01991184Phase 1
- In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose RadiotherapyCompletedNCT01976585Phase 1/2
- Bortezomib Maintenance in High Risk DLBCLStatus unknownNCT01965977Phase 2
- Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell LymphomaCompletedNCT01965119Phase 2
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- AZD6738 First Time in Patient Multiple Ascending Dose StudyCompletedNCT01955668Phase 1
- Treatment of Diffuse Large B Cell LymphomaStatus unknownNCT01949818Phase 4
- Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT01944943Phase 2
- Rituximab + GM-CSF in Patients With Follicular B-Cell LymphomaCompletedNCT01939730Phase 2
- GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01933516Phase 1
- Dose-adjusted EPOCH-R in MYC Positive DLBCLTerminatedNCT01914718Phase 2
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
- The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.Status unknownNCT01865058
- Treatment for Advanced B-Cell LymphomaCompletedNCT01859819Phase 2
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedNCT01854606Phase 1
- Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.WithdrawnNCT01854372Phase 2
- R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.TerminatedNCT01848652Phase 2
- Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in AdultsCompletedNCT01809600
- Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.CompletedNCT01805557Phase 2/3
- A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell MalignanciesCompletedNCT01805375Phase 1
- Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCLStatus unknownNCT01804127Phase 2
- Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell LymphomasStatus unknownNCT01799083Phase 1/2
- A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma PatientsStatus unknownNCT01793844
- Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell LymphomasCompletedNCT01788189Phase 1/2
- Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin LymphomasStatus unknownNCT01786018Phase 2
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell LymphomaCompletedNCT01766583Phase 1
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaCompletedNCT01742988Phase 1
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
- An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell LymphomaTerminatedNCT01724294
- Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaCompletedNCT01722305Phase 1
- A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell NeoplasmsCompletedNCT01704963Phase 1
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
- Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1